key: cord-0746609-8b78duir
authors: nan
title: Full Issue PDF
date: 2020-07-31
journal: JACC: Cardiovascular Imaging
DOI: 10.1016/s1936-878x(20)30467-8
sha: 123a2f8117480098cc78ea1c7dc49f47d7179a7e
doc_id: 746609
cord_uid: 8b78duir

nan

are disclosed with the appropriate detail regarding category and amount, and managed appropriately for building consensus and voting, the JACC Journals program believes that potential bias can be avoided and the final published document is strengthened since the necessary expertise is accessible. has approved the study protocol. If radiation is used in a research procedure, the radiation exposure must be specified in the Methods.

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in your paper. Patients have a right to privacy. Therefore, identifying information, including patients' images, names, initials, or hospital numbers, should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes, and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian, next of kin, or other legally authorized representative). If consent is subject to conditions, the editorial office must be informed.

Written consents must be provided to the editorial office on request.

Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission. Animal investigation must conform to the "Position of the American Heart Association on Research Animal Use," adopted by the AHA on November 11, 1984 The JACC Journals have an ethics committee comprised of 7 members, which oversees quality control and will look into the issues of concern, if any. Authors must agree to the following ICJME statements. These questions will be part of the submission process and manuscripts will not be reviewed until they are confirmed: 1) The paper is not under consideration elsewhere; 2) none of the paper's contents, with the exception of abstracts, have been previously published; 3) all authors have read and approved the manuscript; 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; 5) the full disclosure of any relationship with industry (see "Relationship with Industry

Policy") or that no such relationship exists. Exceptions must be explained. If there is no conflict of interest, this should also be stated in the cover letter.

The corresponding author should be specified in the cover letter, who will receive all editorial communications. The Editorial Office will contact the corresponding author for submission queries.

A short paragraph telling the editors why the authors think their paper merits publication priority may be included in the cover letter. Potential reviewers may be suggested in the cover letter, as well as reviewers to avoid.

In order to add or remove any authors after acceptance of their paper, all listed authors at the time of acceptance need to provide written approval to the JACC Journals' editorial office prior to the scheduling and publication of the paper.

Because of the printed page limitations, the Editors require that manuscripts not exceed 5,000 words (including references and figure legends).

Note that if you are asked to revise your paper an alternate word limit may be specified by the Editors. An outcomes expert/associate editor will review such manuscripts after provisional acceptance. If needed, the Editors will work with the authors in revising the manuscript to highlight the important features of the manuscript. Illustrations and tables should be limited to those necessary to highlight key data. Please provide gender-specific data, when appropriate, in describing outcomes of epidemiologic analyses or clinical trials; or specifically state that no gender-based differences were present. Basic science or experimental studies should have potential clinical applicability. We would prefer manuscripts that offer an algorithmic approach to the use of diagnostic modalities for the best cost-effective use in clinical medicine.

Ethical Approval (required): Please denote that your study received the proper ethical oversight in both your cover letter and your Methods section.

For manuscripts reporting data on human subjects, note institutional review board/ethics committee approval (or formal review and exemption), including the specific name of the board or committee. For studies involving animal experiments, note that the study complied with all institutional and national requirements for the care and use of laboratory animals and, if applicable, received animal care and use committee approval. State the animal-handling protocol in your Methods.

The manuscript should be arranged as follows: 1) title page; 2) structured abstract and key words; 3) condensed abstract; 4) abbreviations list; 5) text; 6) acknowledgments (if applicable); 7) references; 8) figure titles and legends; and 9) tables. Page numbering should begin with the title page.

iREVIEWS (STATE-OF-THE-ART IN IMAGING). Editors welcome reviews on integrated cardiovascular imaging and multi-modality imaging in an attempt to provide the best practice guidelines for general cardiologists.

Imaging reviews must adhere to preferred length guidelines and would be accompanied by an unstructured abstract. Please contact us with suggestions before you start to prepare such review articles. Though often presented within the context of a clinical scenario, this section is not meant to be a vehicle for case reports or a substitute for "Images in Medicine" like features. It is expected that submissions will typically involve images from a number of subjects. Only submissions that align closely with the above criteria will be processed for this section and will be subject to regular peer review. Upon provisional acceptance, we may request 2 sets of glossy or laser print (clean copies will suffice) hard copies of the figures. Glossy prints should be provided for all half-tone or color illustrations. All graphs and line drawings must be professionally prepared on a computer and reproduced as high quality laser prints. Indicate the first author's last name ( This illustration must be accompanied by a legend (title and caption). The Central Illustration must be an original image and, for copyright reasons, cannot be adapted or reprinted from another source.

Updated April 2020 TABLES   Tables should be typed double-spaced on separate pages, with the table   number and title centered above the table and explanatory notes below   the table. Use Arabic numbers. Table numbers 

Authors are encouraged to enhance their manuscript with media files, additional images, web-based calculators, and other material that does not fit into the usual format of an article but that helps communicate results and/or educate the reader.

Inclusion of videos in the published paper is at the discretion of the Editors:

1. Video submissions for viewing online should be submitted as MP4 files only. The Journal office will not accept any other file formats.

Please refer to the guidelines below on quality checking the videos before submission:

You can use any video conversion tool that supports MP4 format with codec setting for H.264 (Â264). In some tools, it may also be known as MPEG-4 Part 10 or H.264/AVC. This format provides an excellent quality, performance, and file size. It is also widely supported by media players, including mobile devices.

An example of a free open-source tool is HandBrake (https:// handbrake.fr/docs/en/latest/table-of-contents.html). Please note that troubleshooting videos for various other tools is beyond the scope of this document or JACC staff.

2. Videos should be no larger than 15 MB. Larger videos will require longer download times and may have difficulty playing online.

Videos should be restricted to the most critical aspects of your research. A longer procedure can be restructured as several shorter videos (each no more than 3 minutes) and submitted in that form. CMR provides accurate measurements of flow and has been validated in vitro and in vivo (4, 5) . CMR methodology is not affected by regurgitant orifice shape and quantifies TR regurgitant volume (TR RV ).

Furthermore, blood flow velocities can be measured from the entire region of interest without assuming a flat flow profile. For example, CMR measurements of mitral regurgitation volume successfully identified patients with severe MR and adverse outcomes (6) . Likewise, CMR is the gold standard for right ventricular (RV) size and ejection fraction (EF) (7) . TR RV is obtained on CMR as the difference between the stroke volume RA enlargement was present if RA volume index was >39 ml/m 2 in males and >33 ml/m 2 in women (8) .

Echocardiographic analyses were performed without knowledge of CMR measurements. ASE cutoff values for TR severity using PISA were based on a study that applied the correction factor (10) . In several patients, underestimation of EROA and regurgitant volume occurs. Therefore, the previously validated correction factor is needed (9, 10) . The first parameter evaluated was CW Doppler of the TR jet. In the presence of a dense and triangular jet, the next step is to examine hepatic vein flow.

With systolic reversal, severe TR was present. In the absence of hepatic vein flow signal or absence of systolic flow reversal, and if RV size was enlarged with normal FAC, severe TR was present. If RV size was normal or the right ventricle was enlarged but with reduced FAC, quantitation with VC, EROA, and TRRV was sought to determine TR severity.

If the CW Doppler jet was faint and incomplete or dense but rounded, the next step was evaluation of Left ventricular (LV) and RV volumes, mass, and EF were measured per CMR guidelines (12) . LV 

replacement fibrosis was assessed (13) . Left atrial and RA volumes were measured using biplane area-length and single plane area-length methods, respectively (14) . Tricuspid annular diameter was measured in the 4-chamber view in early diastole (15) . After correction, instantaneous flow rate, EROA, and TR RV were not significantly different at the 4 aliasing velocities ( Table 3 ). There were no statistically (42) 19 (28) 18 (29) 0.064

Values are mean AE SD or n (%). Diagnosis of heart failure was based on symptoms and signs of pulmonary or systemic congestion along with chest radiographic findings, serum natriuretic peptide levels, and echocardiographic findings. *p < 0.05 vs. patients with moderate or severe TR. †p < 0.05 vs. patients with severe TR. Next, all patients included in the analysis of hierarchal approach accuracy (n ¼ 337) and the 303 patients (in whom conclusions about TR severity could be reached) included in the analysis of the 2017 ASE guidelines were evaluated for agreement with CMR.

The hierarchal approach had significantly higher agreement with CMR (p ¼ 0.016). Table 6 presents the agreement between echocardiography and CMR with patients classified into 2 groups: severe and nonsevere TR.

The agreement between echocardiography (hierarchal approach) and CMR was evaluated in the subgroup of 33 patients with eccentric TR jets. There were 11 patients with severe TR by CMR. TR was deemed severe in 9 of the 11 patients by echocardiography, and in the other 2, TR was graded as moderate. There were 7 patients with moderate TR by CMR, and 5 of the 7 were deemed to have moderate (7) 42 (14) 78 (26) Total 189 (62) 60 (20) 54 (18) 303 (100) In 237 patients of the derivation cohort using the hierarchal approach Echocardiography mild 112 (47) 21 (9) 0 (0) 133 (56) Echocardiography moderate 26 (11) 15 (6) (24) Echocardiography severe 0 (0) 2 (2) 12 (12) 14 (14) Total 67 (67) 16 (16) 17 (17) 100 (100) Values are n (%).

ASE ¼ American Society of Echocardiography; CMR ¼ cardiovascular magnetic resonance. (8) (9) (10) . The use of CMR to assess tricuspid valve regurgitation also requires expertise to accurately measure RV volumes and acquire pulmonary valve flow parameters. Finally, in the study of Zhan et al., (5) an RVol of $45 ml was defined as severe TR. This value has not been validated either for CMR or for echocardiography, and recent studies and editorials have proposed larger values for torrential and massive TR (11) . In spite of these limitations, Zhan et al. (5) When viewed from a different perspective, these results also suggest that in addition to the quantitation of TR, the impact of the latter on the right heart is also (8).

LV function can modify RV function by either indirectly via pulmonary circulation or through direct ventricular interaction (9, 10) . In patients with LBBB, there is typically abnormal contraction of the interventricular septum with marked early systolic shortening and leftward motion (11) (12) (13) . This is followed by lengthening and rightward septal motion when the late-activated LV lateral wall starts contracting (14, 15) .

Because the septum is an important contributor to RV function (16) , this inefficient septal motion may also affect the right ventricle. Theoretically, rightward septal systolic motion assists RV ejection, which may be of particular importance in a failing right ventricle. 

Both the clinical and experimental study demonstrated that, during LBBB, there was an abnormal RV free wall contraction pattern in early systole, which was reduced by CRT (Central Illustration, Figure 2 ).

These results are presented in detail in the following section.

STUDY. Longitudinal strain analysis demonstrated an abnormal contraction pattern with a distinctive early systolic shortening ( Figure 2) Effects of LBBB. The animal study demonstrated identical abnormal RV contraction pattern, as seen in patients (Central Illustration, Figure 2 ). This appeared immediately when LBBB was induced. LBBB slowed RV pressure rise ( Table 1) . The increase in early systolic shortening in the RV free wall occurred during low RV pressure (Central Illustration) with a corresponding decrease in regional work ( Figure 3 , Table 1 ). Similarly, reductions in regional septal ( Figure 3 ) and LV short-axis work were seen, coinciding with increased early systolic septal shortening and leftward septal motion, respectively.

This was opposite to the LV lateral wall where regional work was increased ( Table 1 , Figure 3 ). The ventricular diameter traces also demonstrated that the typical septal flash seen in the LV diameter trace had its counterpart in the RV diameter trace (opposite flash) (Central Illustration), and an increase in RV short-axis work ( Table 1) .

Effects of CRT. CRT reduced the duration of RV pressure rise and caused a rightward and upward shift of the early systolic RV free wall pressure-dimension relationship ( Figure 4 , Table 1 ). Furthermore, early systolic shortening during low pressure was reduced, and regional RV free wall work was increased ( Figures 3 and 4) , despite no change in total shortening ( Figure 3 ). Finally, CRT reduced septal flash with a corresponding decrease in RV short axis work and increase in LV short-axis work ( Figure 4 , p < 0.05) ( Figure 6 ). The corresponding early systolic stretch of septum resulted in increased Representative findings from an animal experiment during LBBB and CRT. During LBBB, the early systolic shortening in the RV free wall and septum coincided with the abnormal septal motion (LV and RV short-axis diameter traces), and the early systolic stretch in the LV lateral wall (all in red). CRT reduced the early systolic shortening in the RV free wall. The concomitant early systolic septal shortening and the LV lateral wall early systolic stretch were also reduced. Furthermore, septal flash and rebound stretch were minimized as seen in both RV and LV diameter traces. In the electrocardiogram, aortic valve opening (AVO) and closing (AVC) as were seen in the aortic pressure curves (not given 

This study demonstrates that LBBB and subsequent application of CRT have instantaneous mechanical effects on RV function (Central Illustration, Figure 2 ).

In patients with LBBB, there was an abnormal early systolic shortening in the RV free wall, which coincided and correlated with early systolic septal shortening. In the animal study, identical findings were seen and allowed us to study the underlying mechanisms in detail. It demonstrated how the abnormal pressure and thereby reduced regional work, even though total shortening was unchanged ( Table 1) .

Despite reduced septal contraction during LBBB, the left ventricle still supports the right ventricle by pushing the septum rightwards driven by the late, but enhanced, contraction in the LV lateral wall. The early systolic septal shortening causes a systolic preexcitation stretch of the late-activated LV lateral wall (Central Illustration), which increases regional preload on this wall (14, 25) . Subsequent vigorous contraction of the LV lateral wall causes a systolic rightward shift of septum. This is evident as increased RV short-axis work ( Table 1 , Figure 4 ). Figure 5 ). By this approach, we confirmed the direct mechanical interaction between the LV and the RV, as LV end-diastolic pressure was unchanged ( Table 1) . The demand on the RV free wall increased (Figure 4) , which was demonstrated by 

(Left) Pressure-segment length loops from the RV free wall during LBBB (red) and

CRT (green). CRT increased regional work in the RV free wall illustrated by the shading because of less inefficient shortening against low pressure during early systole. (Right)

The effect of septal motion on RV function was indicated by RV short-axis work. From the LBBB loop (red), the leftward septal motion during early systole (increasing diameter) during low pressure followed by rightward septal motion (shortening of diameter) at higher pressure is seen. This increases RV diameter work as seen as the shaded area. It was a result of the delayed contraction in the LV lateral wall and the work transferred by the septum. During CRT, RV short-axis work was reduced because of reduced contribution of the LV lateral wall to the RV work. Thus, right ventricle "lost"

its help from the LV lateral wall mediated by the septum during CRT, and RV free wall increased its regional work as seen by the shading in left panel (see Central Illustration

for the separate ultrasonic traces). CRT ¼ cardiac resynchronization therapy;

LBBB ¼ left bundle branch block; RV ¼ right ventricular; RVP ¼ right ventricular pressure. 

Pressure-segment length loops, representing regional work, at LBBB (Animal A) and LV lateral wall pacing (Animal B). Please note the opposite directed changes in workload during the 2 interventions. The latest activated regions had increased workload resulting from initial lengthening compared with the early activated regions, which had early systolic shortening. LBBB ¼ left bundle branch block; LV ¼ left ventricular; LVP ¼ left ventricular pressure; RV ¼ right ventricular; RVP ¼ right ventricular pressure. in a heart with left ventricular (LV) failure (left column) and in a heart with both LV and right ventricular (RV) failure (right column). Simulations were performed with the CircAdapt model of human cardiovascular system dynamics (11) . LBBB was simulated by delaying mean LV free wall activation time 60 ms relative to mean septal and RV free wall activation times. CRT was simulated by acutely synchronizing mean activation times of all 3 ventricular walls at an atrioventricular delay of 132 ms.

The bottom row presents CRT response for both LBBB hearts. CRT response is defined as the acute pacing-induced change of cardiac output relative to the baseline cardiac output of 4.1 l/min in the LBBB simulations. Heart rate was kept constant at 80 beats/min during all simulations. LVEF ¼ left ventricular ejection fraction;

and circulation (CircAdapt, Maastricht University, Maastricht, the Netherlands), which has been extensively used for simulation of mechanics and hemodynamic status in the failing heart with LBBB and during its treatment with CRT (3, 13) . Figure 1 shows the simulated strain patterns of the 3 ventric- 

In an earlier study, Van Everdingen et al. (14) showed apparatus. Ischemic mitral regurgitation (IMR) is a common sequela of ischemic cardiomyopathy (ICM) due to underlying regional LV dysfunction, LV remodeling, and mitral annular dilation, all of which lead to impaired leaflet coaptation. The severity of IMR assessed by Doppler echocardiography has been shown to be associated with outcomes (1) (2) (3) (4) . However, despite the association between IMR severity and mortality, there is currently no evidence that surgical correction of IMR is superior to medical therapy (4, 5) . Furthermore, recent conflicting results from percutaneous therapy trials (6, 7) addressing secondary mitral regurgitation (MR) (which includes IMR) have raised questions about the differences in the criteria used for patient selection and for MR severity (8, 9) .

In IMR, the accepted theory is that the problem resides within the LV. Therefore, the complex interplay between LV remodeling, myocardial infarct size (MIS), and volume overload from IMR requires a comprehensive understanding of each of these components and how they combine to result in the associated outcomes. Our group has previously shown that evaluation of LV remodeling (10) and MIS (11) by cardiovascular magnetic resonance (CMR) added incremental prognostic value to conventional clinical and echocardiographic variables in a cohort of patients with ICM and in patients undergoing surgical mitral intervention (12) .

Importantly, these parameters were also associated with the progression of IMR (13), a commonly reported problem after surgical repair from a large contemporary series (14) . Table 1 . Failure registry (20) . The mean time between CMR and echocardiography was 3.8 AE 1.0 days, with 67% of subjects having <5 days between the 2 imaging modalities. Of note, none of the patients had an implantable permanent pacemaker, defibrillator, or resynchronization device in situ at the time of the CMR study. ICD insertion after the CMR study was treated as a time-dependent covariate. To evaluate the effect of MIS on the relationship between MRFraction and patient outcomes, the AUC ¼ area under the curve; CI ¼ confidence interval; EROA ¼ effective regurgitant orifice area; IMR ¼ ischemic mitral regurgitation; ROC ¼ receiver-operating characteristic; other abbreviations as in Table 2 . Table 3 . *Medical risk score includes the following variables: age, body mass index, sex, diabetes, glomerular filtration rate, hypertension, dyslipidemia, medications (beta-blocker, angiotensin-converting enzyme inhibitor/receptor blocker), left or right bundle branch block, QRS duration, and an interaction term for sex and diabetes. †The 2-way interaction of MIS (3 levels) and MRFraction (2 levels) represents a 3 Â 2 categorical variable. The main effects of MIS and MRFraction are included in the model but are not shown here because they cannot be interpreted when the interaction term is in the model. Tables 2, 3 , and 5. Table 2 

The ongoing debate about the differences, similarities, and complementary information of the MITRA-FR and COAPT studies has generated many questions among the medical community regarding the optimal imaging characteristics that define the ideal patient. We believe that our findings are not only timely but also of critical relevance because they add a third dimension: that is, the pathophysiology construct in IMR needs to be expanded not only to include LV remodeling and IMR severity (as currently proposed) but, importantly, to quantify the severity and extent of MIS. Only then we will be able to fully understand who has proportionate and disproportionate IMR. The CMR community at large is ready to provide that comprehensive assessment, which we believe is necessary to improve decision making for our patients and better individualize the available therapies. Mitral Regurgitation) showed a striking benefit of the clip in both categories (10) . As such, COAPT was the first randomized trial to find a mortality benefit of mechanical intervention in secondary MR.

Much has been written in efforts to reconcile the different results of these 2 excellent trials (11) (12) (13) . In MITRA-FR, there was somewhat less severe MR than in COAPT, and the patients' LV volumes were larger in MITRA-FR. These data suggest that something other than the MR (presumably the severity of the cardiomyopathy) was driving the LV enlargement in MITRA-FR, indicating that the MR was more of a bystander than a culprit (11) , whereas in COAPT, the 

MR was likely severe enough to cause damage by itself (tertiary MR) (12) .

The study by Cavalcante et al. (14) in this issue of iJACC may well shed light on the MITRA-FR, COAPT conundrum (14) . BACKGROUND Stress CMR perfusion imaging has established excellent diagnostic utility and prognostic value in coronary artery disease (CAD), but its cost-effectiveness in current clinical practice has not been well studied in the United States.

METHODS A decision analytic model was developed to project health care costs and lifetime quality-adjusted life years (QALYs) for symptomatic patients at presentation with a 32.4% prevalence of obstructive CAD. Rates of clinical events, costs, and quality-of-life values were estimated from SPINS and other published research. The analysis was conducted from a U.S. health care system perspective, with health and cost outcomes discounted annually at 3%. Table 1 .

For each management strategy, health care costs and QALYs were projected to derive incremental costeffectiveness ratios (ICERs). We used $100,000/QALY as a threshold for willingness to pay for health (14) .

The analyses were conducted from a health system perspective over a lifetime horizon, with all costs projected to 2017 dollars, and future health care costs and QALYs discounted at 3% annually (15 Figure 4C) . Either SPECT or CCTA is favored over CMR when performance goes beyond the 95% confidence interval from the input data sources (e.g., when both sensitivity and specificity are >90%). Figure 5 shows the costeffectiveness acceptability curve results for the PSA. The CMR-based decision-making strategy was most likely to be optimal in the PSA using a costeffectiveness threshold of $100,000/QALY. The CMR-based strategy was optimal in 84% of PSA iterations; no imaging was optimal in 16%; and SPECT, CCTA, and immediate XCA were optimal in 0%. Using a cost-effectiveness threshold of $50,000/QALY, no imaging was optimal in 79% of PSA iterations, while CMR was optimal in 21%.

Using a cost-effectiveness threshold of $150,000/ QALY, CMR was optimal in 95% of PSA iterations, and no imaging was optimal in 4% of PSA iterations. 

Stress CMR has been shown in multiple large-scale studies over recent years to be a robust modality for diagnosis and risk stratification of patients suspected of having CAD (6, 9) and determining the physiological significance of coronary stenosis (26) . Compared with clinical standard of care, stress CMR has also been shown to reduce the rate of unnecessary angiographic examinations (27) . Despite the robust body of published research and society recommendations supporting its use (28) , contemporary data on its cost-effectiveness compared with other state-ofthe-art noninvasive modalities remain limited.

In the present study, we used data from the SPINS registry, a contemporary stress CMR multicenter U.S. cohort of patients with stable chest pain syndromes, to develop a decision analytic model to evaluate clinical management strategies. We used updated meta-analyses for noninvasive test sensitivity and specificity, with XCA with selective FFR as the gold standard to diagnose significant CAD (19, 20) . This was chosen given studies showing that anatomic assessment alone of lesion severity has significant limitations (29, 30) . In this model cohort, we found that CMR-based assessment was optimal on the basis of a $100,000/QALY cost-effectiveness threshold for the Finally, the clinical benefit assigned to diagnosis of obstructive CAD in our model was based on a combination of medical and revascularization therapy.

The value of the latter, particularly in stable coronary disease, is controversial (33) and is currently under investigation in an ongoing large randomized trial (34) . How do we interpret these findings? First, the authors should be congratulated for their efforts in developing a coherent decision analytic model, synthesizing contemporary U.S. data from the SPINS study with other published evidence. Importantly, their conclusions appear robust, and we commend the use of PSA to address the joint uncertainty across all parameters, which demonstrates a high probability of CMR being cost effective at $100,000/QALY. Nonetheless, there are potential weaknesses that could be addressed in future analyses; for example, a failure to reflect higher MACE risk in the year following a previous MACE is not in line with previous analyses, and-assuming a constant long-term MACE risk-does not reflect increasing risk with age (14, 15) . Similarly, the model does not reflect increasing costs of patients with increasing age (16) .

The use of common utility values for those with and without obstructive CAD, and the failure to consider disutility arising from nonfatal adverse events associated with ICA-or from recovery from revascularization-is questionable, the impact of which has not been considered in the uncertainty analysis. Finally, the divergence between the results based on "hard" and "all" MACE outcomes needs further consideration, as does the use of common mortality multipliers across these 2 different MACE outcomes. suspected CAD in multiple scenarios (12) . For these reasons, and the fact that a comprehensive ischemia/left ventricle function/viability CMR scan can be performed in as little as 20 min (19) Chaikriangkrai et al. Values are %.

Abbreviation as in Table 1 . (16) (17) (18) (19) (20) (21) (22) . Both ECV and T2 have been shown to be higher in OHT patients compared with healthy controls (16) and correlate well with myocardial edema marker (17, 21) . ECV was also shown to correlate with histological fibrosis (18) . Clinically, previous research has demonstrated possible association of higher ECV and T2 with ACR episodes (23) . Nevertheless, the prognostic value of T1-and T2-mapping markers has not been established in OHT population.

Our study demonstrates that higher ECV during the baseline CMR assessment predicts overall adverse clinical events. We did not find significant association specifically between T1-mapping markers and adverse cardiac events. This association may suggest potential multifactorial causes of higher ECV in OHT patients. Chaikriangkrai et al. markers of cardiac allograft function were found to be associated with cardiac allograft vasculopathy and adverse clinical outcomes (44, 45) .

We demonstrate independent association of higher Should potential mechanisms such as cumulative insults from injury, side effects from immunosuppressive medication, biopsy-negative rejection, and subclinical chronic inflammation and CAV leading to higher T2 be confirmed, these data support a role for CMR in guiding therapy by identifying those who may benefit from novel therapies (14) contrast-enhanced coronary CTA (Figure 1) napkin-ring sign) as previously defined (12) . As per the CAD-RADS definition, the "V" modifier for "vulnerable plaque" was defined as 2 or more HRP features in at least 1 coronary plaque/segment (17) . Table 1 ). Values are mean AE SD or n/N (%). Body-mass index is the weight in kilograms divided by the square of the height in meters. *A family history of premature CAD was defined as diagnosis of the disease in a male first-degree relative before 55 yrs of age or in a female first-degree relative before 65 years of age. †CAD risk equivalent was defined as diabetes, peripheral vascular disease, or cerebrovascular disease. ‡The metabolic syndrome was defined according to consensus criteria of the American Heart Association and the National Heart, Lung, and Blood Institute. §Sedentary lifestyle was defined by the patient as not participating in regular physical activities at least 1 time per week over the previous month. kRacial or ethnic minority group was self-reported, with the status of "minority" being defined by the patient. ¶Risk factors included hypertension, diabetes, dyslipidemia, family history of premature CAD, and tobacco use. #Combined Diamond and Forrester and Coronary Artery Surgery Study risk scores range from 0 to 100, with higher scores indicating a greater likelihood of obstructive CAD. **The type of angina was reported by the study-site investigators.

ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin-receptor blocker; ASCVD ¼ atherosclerotic cardiovascular disease; BMI ¼ body mass index; CAD ¼ coronary artery disease. Figure 1) and was significantly associated with a higher hazard for the composite Values are n/N (%), unless otherwise indicated. *Presence of "vulnerable plaque" defined as 2 or more high-risk plaque features in at least 1 coronary plaque/segment. Adverse events include all-cause death, hospitalization for unstable angina, and MI. Overall, the incidence of the composite endpoint increased across CACS categories (p < 0.001) as well as CAD-RADS stenosis categories within each CAC group (p < 0.001), as displayed in Table 4 . Table 6 .

In a large contemporary trial of patients with stable chest pain randomized to coronary CTA, we found that the CAD-RADS reporting system had greater severe CAD ($50% stenosis of left main [LM] or $70% in any major vessel/branch) †Normal (absence of coronary atherosclerosis), mildly abnormal (nonobstructive CAD: 1% to 69% stenosis in any major vessels/branch or <50% LM stenosis), moderately abnormal (obstructive CAD: $70% stenosis in 1 major vessel/branch), and severely abnormal (high-risk CAD: 2 or more vessel disease ($70%) or $50% LM stenosis or $70% proximal LAD stenosis) CAD-RADS ¼ coronary artery disease reporting and data system; CAD-RADS 0 ¼ no plaque/ stenosis; CAD-RADS 1 ¼ 1% to 29% stenosis; CAD-RADS 2 ¼ 30% to 49% stenosis; CAD-RADS 3 ¼ 50% to 69% stenosis; CAD-RADS 4a ¼ 70% to 99% stenosis; CAD-RADS 4b and 5: $50% LM stenosis or $70% stenosis in 3 vessels or total occlusion.

Bittner et al. Values are n (%).

CACS ¼ coronary artery calcium score; other abbreviations as in Table 2 . Values are n/N (%). Tables 2 and 3 . 

Excellence. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin (update The analysis of coronary 18 F-fluoride activity has been previously described (6, 7) . In brief, visual assessment for increased coronary 18 SAMPLE SIZE. In patients with increased coronary 18 F-fluoride uptake, we previously reported that mean AE SD troponin concentrations were more than double those in patients without increased coronary 18 Ffluoride uptake (7.9 AE 9.3 ng/l vs. 3.1 AE 1.9 ng/l; p ¼ 0.047) (7) . It was estimated that ticagrelor would reduce the troponin concentration by one-half. Fortyeight patients per treatment arm were required to achieve 80% power at 2-sided p < 0.05. After allowing for 15% dropout, we estimated that 55 patients will be required per treatment arm. Previous studies had found that 45% of patients with advanced but stable coronary artery disease exhibited increased coronary 18 F-fluoride uptake; thus, a total sample size of 250 patients was estimated to be required to identify 110 patients with increased coronary 18 Figure 2 ).

The geometric mean troponin I concentration at baseline was 3.8 (geometric SD: 2.9) ng/l in patients effect using ticagrelor (3, 14) . Second, our unique study design enabled high-risk patients with multivessel coronary disease and in vivo evidence of disease activity to be precisely phenotyped before randomization in a manner that can seldom be achieved in larger clinical outcome trials (3, 15 Moss et al. has clinical relevance, as these regions may lead to atherosclerotic plaque rupture manifesting as myocardial infarction, stroke, or aneurysm rupture (7, 19, 20) . In our cohort, the frequency of 18 A key question is whether troponin measurements below the 99th centile reflect subclinical plaque rupture with accompanying distal microvascular embolization, as has previously been posited (21) . In this regard, some therapies directed at reducing the risk of atherosclerotic plaque rupture, such as pravastatin, both modify troponin concentrations and reduce the risk of myocardial infarction (22, 23) . In contrast, strategies that have failed to show a reduction in cardiovascular events in the context of stable coronary artery disease, such as coronary revascularization, attenuation of plaque inflammation, and Abbreviations as in Table 3 .

inhaled therapies for respiratory disease, have not correlated with a reduction in serial troponin concentration (24) (25) (26) (27, 28) . In this study, high-sensitivity cardiac troponin I concentrations were higher in patients with 18 F-fluoride activity, although the differences were small and below the established risk stratification threshold of 5 ng/l (9, 22, 29) . It therefore seems unlikely that troponin at these concentrations reflects subclinical plaque rupture, and it is perhaps unsurprising that ticagrelor treatment did not result in an early or late reduction in troponin concentration.

Antiplatelet Therapy

Ticagrelor Placebo Previous reports have suggested that there is a high incidence of subclinical intracoronary thrombus in patients with apparently stable coronary artery disease. Indeed, some have suggested that this outcome occurs in as many as 1 in 7 patients (8) . If this is the case, it would seem that intracoronary thrombus does not track with troponin. This suggests that better noninvasive markers of coronary thrombosis, such as novel PET tracers (30) or noninvasive imaging (31) , are needed to use as biomarkers of cardiovascular risk and antithrombotic therapeutic efficacy.

STUDY LIMITATIONS. The current study had a modest sample size to assess the impact of ticagrelor on a readily available plasma biomarker, and a larger study would be required to assess clinical outcomes of ticagrelor use in patients with stable coronary artery disease and coronary 18 Two decades ago, the concept of therapeutic "plaque passivation" was developed; in theory, medical therapies might be applied to those with coronary plaques prone to disruption, such that risk for progression to MI might be prevented. With tools to detect such "vulnerable" high-risk plaques, application of therapies to stabilize or "passivate" the coronary artery might be expected to improve outcomes in affected patients (3) . Options for this approach included aggressive lipid lowering, anti-inflammatory therapies, and antiplatelet therapies, along with the concept of "plaque sealing" by using percutaneous coronary intervention to cover plaques likely to progress to disruption. None of these approaches gained traction, however, as the ability to accurately, easily, and reproducibly detect plaques prone to rupture in a cost-effective manner was limited. Most efforts focused on invasive imaging techniques.

Although concentrations of cardiac troponin informed benefit from antiplatelet therapy in those with acute coronary syndrome (4), use of biomarkers to inform therapies in more stable patients remained limited due to the inability of conventional assays to sensitively measure troponin in more stable situations.

This has changed, however.

Recent refinement in troponin assays has facilitated the ability to measure troponin concentrations in $50% of normal individuals (5) . In this regard, the prevalence of myocardial injury (defined as an elevated troponin concentration >99th percentile) among patients with stable CAD varies depending on the clinical setting in which the troponin concentration was measured; however, it may be as high as 54% in patients with obstructive CAD (6). Among patients with obstructive CAD, myocardial injury is an independent predictor of all-cause mortality, cardiovascular mortality, and incident MI (6) . Curiously, this risk seems to be within months of index high-sensitivity cardiac troponin (hscTn) measurement (but not longer), implying that the biomarker reflects an active coronary lesion (7) . This theory has been borne out by studies reporting modest associations between higher concentrations of hscTn with more diffuse CAD and similar associations with high-risk plaque (8, 9) . This creates a hypothetical construct linking plaque instability to processes leading to myocardial injury, notably including microembolism and "downstream" Perhaps the largest limitation of the study (11) is the assumption that concentrations of hscTnI associated with high-risk plaque are linked to a biologic process that may be treated with antiplatelet therapy; of course, this is why a study such as this is performed-to explore plausible means by which to contain myocardial injury. Selection of intensive antiplatelet therapy is logical, and although the results were disappointing, it is not to say this approach cannot work; that said, it is necessary to concede that associations between concentrations of hscTn and high-risk plaque are modest, and myocardial injury is often seen in the absence of acute ischemia (13, 14) .

Although ticagrelor did not reduce hscTnI concentrations even in those with higher concentrations of the biomarker, relatively few subjects fell into this category, potentially increasing the risk for a type II error. Indeed, it is tempting to speculate that the specificity for an ischemic mechanism for myocardial injury would be enriched at higher troponin concentrations.

Moss et al. (11) are to be congratulated for taking this quest on: 20 years after the initial concepts of plaque "passivation," we are still actively trying to find ways to mitigate the higher risk plaque vulnerable to disruption. With more refinements in ability to assess and understand such coronary lesions, the hope would be for a precision-based approach to further reduce risk for acute MI. The so-called internal cardiac work is neglected.

This is mechanical work done by the myocardium, not generating stroke volume or blood pressure but, instead, stretching elastic elements in the myocardium (therefore, sometimes also called potential energy) (Figure 1) . (often presented as k mono ), whereas others use biexponential fitting and some a more complex concept with pharmacokinetic modeling to calculate both the wash-in rate and the wash-out rate from the same curve (12, 13) . A commonly used and simplified approach applicable to serial investigations in the same subjects is the workmetabolic index (WMI):

with the units mm Hg  ml  m -2 , where SBP is systolic blood pressure, SV i is stroke volume index, HR is heart rate, and k mono the monoexponential time constant of decay for 11 C-acetate (4). The WMI, unlike MEE, does not correct for LV mass and, therefore, is better for serial intraindividual comparisons than for comparing efficiency between individuals. Also, the WMI is different from MVO 2 in units and numeric value.

In this paper, for simplicity, we use the term myocardial efficiency synonymously with MEE. It is important to understand that myocardial efficiency, mass were measured (see Table 1 Several studies have investigated the relation of myocardial efficiency to sex, obesity, and diabetes.

Myocardial efficiency was lower, and MVO 2 higher, in female, obese, and diabetic individuals (18) . In a study of 30 obese patients before and after weight reduction by diet or gastric bypass, MVO 2 decreased, but myocardial efficiency remained largely unchanged (19) . The influence of age on myocardial efficiency is unclear. Surprisingly, physical fitness seems not to play a major role for mechanical efficiency. In a study comparing 13 highly trained endurance athletes versus 13 age-matched nonathletic control individuals, similar myocardial efficiency at rest and during exercise was found (20, 21) . MVO 2

The examination takes approximately 25 min and results in an effective radiation dose of approximately 1.6 mSv. A few seconds after a brief intravenous bolus injection of 11 C-acetate, the tracer (A) is detected in the right ventricle, (B) passes through the lungs and into the left ventricle and aorta 10 to 20 s later, and finally (C) enters the myocardium. In C, Myocardial extraction is proportional to blood flow, and accumulation is high. Intracellularly, 11 C-acetate is enzymatically trapped as 11 C-acetyl-coenzyme A, which is transported into the mitochondria and metabolized. (C to E) The radioactive isotopes leave the myocardium as radiolabeled carbon dioxide through expiration in the lungs. The rate of 11 CO 2 formation is linearly related to oxygen uptake and, thus, myocardial oxidative metabolism. (F) The clearance rate can be calculated for each voxel, which can be plotted as a quantitative image of oxygen uptake. PET ¼ positron emission tomography. Table 1 ) (22) . Early on, researchers using invasive measurement of hemodynamics and oxygen uptake found preserved oxygen uptake, reduced LV work, and, thus, reduced myocardial efficiency in patients after myocardial infarction, modestly correlating with ejection fraction (23) . In contrast, presence of coronary artery disease without infarction did not affect myocardial efficiency. In myocardial scar, regional MVO 2 and regional efficiency are decreased (24) . Under conditions of preserved myocardial viability but decreased contraction, such as stunning or hibernation, regional efficiency is reduced due to largely preserved MVO 2 despite contractile dysfunction.

Myocardial efficiency clearly affects prognosis in patients with dilated, nonischemic cardiomyopathy. However, in a small study, Tuunanen et al. (36) found that a drug reducing free fatty acids by blocking lipolysis reduced stroke volume, but not oxidative metabolism, in patients with dilated cardiomyopathy, thus leading to decreased myocardial efficiency. In contrast, in healthy control individuals, stroke volume also decreased, but efficiency was preserved by a commensurate reduction in oxidative metabolism.

Thus, the validity of the concept of metabolic modulation remains unproven.

Several agents, such as ranolazine, perhexiline, and trimetazidine, have been proposed and tested in small patient cohorts, mostly to alleviate angina.

Ranolazine has been shown in a canine model of chronic heart failure to improve myocardial efficiency by raising cardiac output at unchanged oxygen uptake, in contrast to dobutamine, which increased cardiac output at the expense of a parallel increase in oxygen uptake (37) .

Another theoretically attractive approach to metabolic modulation in heart failure is to supply specific beneficial energy substrates to the heart.

Ketone bodies, which theoretically may provide a better balance of energy generation to consumed oxygen than glucose or fatty acids, might therefore be a therapeutic option in heart failure. Very recently, the short-term infusion of the ketone 3hydroxybutyrate in patients with heart failure with reduced ejection fraction was found to promptly increase ejection fraction and cardiac output, as well as proportionally increased myocardial oxygen uptake, without compromising myocardial efficiency measured by PET, thereby possibly avoiding deleterious long-time effects, although this was not tested (38) . Another candidate drug for the optimization of cardiac metabolism in heart failure is empagliflozin, which is used for the treatment of type 2 diabetes.

Empagliflozin has been shown to increase invasively measured myocardial efficiency in postinfarction heart failure in an experimental, nondiabetic pig model (39) . This study showed a metabolic switch to more free fatty acid and ketone body and less glucose metabolism in animals treated with empagliflozin for 2 months after infarction compared with those receiving placebo.

The effect of exercise on the failing heart was assessed in a study of patients with dilated Figure 4 , which is from a patient with heart failure and left bundle branch block. There is markedly reduced septal work, which is likely to improve with cardiac resynchronization therapy. The wasted septal work is the result of contractions in the LV lateral wall and implies that the septum absorbs energy from the LV free wall. The increased work load on the free wall is a stimulus for remodeling, which contributes to the development or progression of global LV dysfunction and, ultimately, congestive heart failure. In patients with myocardial scar, these contraction patterns can be different from the typical left bundle branch block pattern referred to earlier (44) . Several studies have suggested that the extent of wasted energy in patients with dyssynchronous heart failure may be useful for identifying candidates for cardiac resynchronization therapy (45) (46) (47) , and this approach is currently being tested in a prospective study. However, strictly speaking, regional myocardial external efficiency was not evaluated, because this would necessitate assessment of regional MVO 2 . However, another group has compared myocardial efficiency calculated from MVO 2 by 11 C-acetate PET to myocardial work calculated by strain-pressure loops in patients with amyloidosis, finding a fair relationship (48) . In this context, MEE is not equivalent to myocardial work efficiency, a recently introduced parameter based on LV pressure-longitudinal strain loops that does not involve any measurement of oxidative metabolism and, therefore, uses "efficiency" in a different sense.

Hypertension increases stroke work and thus increases myocardial oxygen uptake; because both increase, myocardial efficiency is largely unchanged.

However, once the LV hypertrophies due to hypertension, the oxygen uptake per gram of myocardium becomes normal again (49, 50) . (54, 55) . In persons who were mutation carriers without phenotypic expression of hypertrophic cardiomyopathy (i.e., without LV hypertrophy), myocardial efficiency was significantly lower than in control individuals but higher than in patients with manifestly hypertrophic cardiomyopathy (15) . These findings confirm earlier work (56) showing a "mechano-energetic uncoupling" in hypertrophic cardiomyopathy that is also observed in other types of myocardial hypertrophy, such as aortic stenosis or hypertension. surgery. The WMI using the forward stroke volume (i.e., the effective stroke volume) was significantly improved by surgery, whereas the WMI using the total LV stroke volume incorporating the regurgitant volume was unchanged (60) . The WMI also improved after surgery in secondary mitral insufficiency in

Myocardial external efficiency is a performance measure of the myocardium linking metabolism to mechanical work that can be measured by PET.

The diagnostic and prognostic potential of myocardial efficiency in heart disease, especially heart failure, is only beginning to be explored. Decreasing costs and automation of PET will make this information increasingly available and may in the future guide the selection of drugs and therapeutic interventions in heart disease.

Because of prohibitive costs and low availability due to the need for a cyclotron, evaluation of myocardial efficiency has in the past been a research tool. Both restrictions will decrease dramatically in the near future, enabling myocardial efficiency as a fundamental cardiac performance parameter to be tested in larger studies and making translation to clinical practice possible. Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic (11) . In this paper, we provide a comprehensive review of the multiple imaging modalities that can be used to assess coronary MVD in the absence of obstructive epicardial disease ( Table 1) .

Before understanding the underlying technicalities required to quantify MVD, baseline knowledge of the functional anatomy of the coronary circulation is required ( Figure 1 ). There are 3 components of the coronary arterial vasculature that are subdivided by the size of the arterial structure, its capacitance, and its resistance to myocardial blood flow (MBF) (12) . The initial component is the epicardial coronary arterial tree (5 mm to 400 mm in diameter), which has near negligible coronary resistance in the absence of stenosis and consists of essentially conductive vessels.

The pre-arteriole vessels follow (100 to 400 mm in size); these are still largely extramyocardial and respond primarily to flow and intravascular pressure to deliver a narrow pressure range to the arterioles (12) . The third and distal component is the intramural arterioles (40 to 100 mm), which have the primary responsibility of matching blood supply to myocardial oxygen consumption. The distal capillary and venule systems are low-resistance capacitance vessels, holding up to 90% of the total intramyocardial blood volume (13) . The pressure gradient between the aortic root and the right atrium is the primary driving force of flow across the myocardium (14) . MBF is defined as the amount of flow through the coronary vessels over time and is typically expressed as blood flow per gram of myocardium (12) .

Under normal conditions, there are elegant mechanisms of autoregulation in the pre-arteriolar and arteriolar microcirculation that allow stable coronary blood flow across a large range of perfusion pressures (12, 15) . For example, in the setting of hypotension, the driving pressure would decrease, and autoregulatory mechanisms would subsequently decrease microvascular resistance to attempt to maintain adequate blood flow (14) . There are multiple autoregulatory mechanisms aimed at manipulating arterial tone. There is myogenic constriction of the distal prearterioles in response to increased pressure. Arterioles can decrease or increase their diameter in response to flow changes, leading to shear stress, which induces dilation of larger conductive vessels.

In addition, arterioles can regulate blood flow in response to metabolites formed when myocardial oxygen demand increases (16) .

In the setting of coronary MVD, there can be a disruption of these adaptive mechanisms, which can be assessed via various noninvasive provocative tests.

One such test is sympathetic stimulation using cold pressor testing. The sympathetic response from a cold stimulus will increase myocardial work and thus a proportionate increase in MBF by metabolically initiated endothelium-related vasodilator forces in the microvasculature (14, 17) . Inotropic stimulation with dobutamine can increase MBF via increased myocardial oxygen demand (14) . However, these methods are not commonly used, and therefore the Coronary Vas- (19) . "MVD" is a broad term; in the absence of obstructive coronary disease, it includes any pathology that may disrupt the microvasculature, including endothelial dysfunction, coronary spasm, inflammation, and atherosclerosis (20) . Changes in arteriolar diameter or microvascular rarefaction with diffuse fibrosis, such as in heart failure with preserved ejection fraction, have been associated with MVD (21, 22) . A reduction in the ratio between maximal hyperemic coronary flow and baseline coronary flow indicates reduced CFR. CFR can vary by sex, age, and the modality used for measurement (23, 24) . Importantly, CFR is a composite measure of epicardial stenosis severity and MVD; however, in the setting of normal epicardial coronaries, abnormal CFR represents MVD (12, 25) . The value that represents abnormal CFR has differed among studies, and values ranging from 1.5 to 2.5 have been used in prognostic studies (20, 26, 27) .

Traditionally, the term "CFR" has referred to the invasive measurement of flow reserve, while noninvasive measuring methods, as discussed in this imaging parameters are also being studied, such as microcirculatory blood volume or microvascular blood volume and intramyocardial blood volume (28) (29) (30) . It has been shown that changes in these parameters or reduction in these parameters can be associated with coronary MVD (31) . This method correlates well with flow acquired from an intracoronary Doppler wire (48, 50) . In addition, abnormal CFVR is associated with adverse cardiovascular events (27, 51 has high first-pass uptake, relatively low radiation exposure (2 mSv), and high myocardial retention but is limited by the roll-off that occurs at high coronary blood flow (67, 71) . Unfortunately, 82 Rb has a lower extraction fraction, has more significant roll-off at high flows, and is associated with higher radiation, making 13 N-ammonia the more preferred agent for accurate MBF quantification, particularly at high flows (71). However, 82 Rb is more commonly used because it requires only an on-site generator as opposed to a cyclotron (71) . It also has been validated against 13 N-ammonia (72) .

The assessment of MBF by PET is primarily performed by post-processing software that performs automated segmentation and AIF measurements during dynamic first pass scanning (Central Illustration) (72) . Depending on the radiotracer used, the postprocessing software will perform the kinetic modeling on the dynamic data to compute the regional and global stress and rest MBF (66, 73, 74) .

The intrasoftware reproducibility of MBF measurements is reasonable, ranging from 4% to 15% (74) (75) (76) .

Some prospective PET studies correlate MVD, defined as abnormal MPR, with adverse prognosis (77, 78 derived MPR and MBF have been particularly useful in analyzing different subsets of populations (82) .

Abnormal flow reserve in patients without overt CAD was independently associated with diastolic dysfunction and increased risk for hospitalization for heart failure with preserved ejection fraction (83) .

There is evidence of abnormal PET-derived MBF in patients with metabolic syndrome and non-insulindependent diabetes (84, 85) . These findings are particularly profound in women, indicating the potential of important sex-related differences in MVD (82) . Women, despite having less obstructive CAD compared with men, are burdened by increased symptoms and similar or worse outcomes (86, 87) .

Also, as recently described, comprehensive quantitative perfusion analysis by PET that includes regional absolute stress flow, relative stress flow, CFR, and quantitative subendocardial perfusion gradients can lead to better diagnostic certainty for MVD (88) . It should be noted that clinically used PET protocols are not capable of accurately quantifying vasodilator-induced subepicardial to subendocardial perfusion gradients because of limitations in spatial resolution. Despite the vast amount of prognostic data in PET-derived blood flows, PET is not without its limitations, which include radiation exposure and cost, depending on which radiotracer is used (72) .

SPECT imaging is the most common nuclear cardiovascular imaging modality but has been limited to date in quantification of MBF because of poor camera sensitivity and temporal resolution with the more common sodium-iodide cameras (44) Table 2) .

The ultimate goal of identifying coronary MVD is to define prognostic differences, therapeutic in- 

The authors discuss the nuances of MBF and MPR quantification in imaging modalities.

Each modality, with advantages and disadvantages, has played a role in detecting MVD.

PET-derived MBF offers the most prognostic data to date on the impact of MVD.

Research on MBF quantification by CMR is growing as CMR becomes more accessible. Transesophageal echocardiography (TEE) has been the pillar of intraprocedural imaging in TTVr, particularly with the tricuspid clip procedure. However, acoustic shadowing of the clip delivery system can limit confirmation of sufficient leaflet insertion during grasping and clip closure. Intracardiac echocardiography (ICE) is a potential adjunctive intraprocedural imaging tool in TTVr with the MitraClip (2), but technology has been limited to 2-dimensional (2D) views; catheter stability can compromise image acquisition and quality. Four-dimensional (4D) ICE may overcome the limitations of TEE and 2D ICE during the tricuspid clip procedure by providing improved tricuspid valve imaging during leaflet grasping. Our paper aims to demonstrate the feasibility of using 4D ICE during TTVr with the MitraClip system in 5 cases at 2 institutions (Figures 1-14) .

Our case series demonstrated the usefulness of 4D ICE in guiding transcatheter tricuspid edge-to-edge repair with the MitraClip system. We believe that this complementary approach of using TEE and 4D ICE can help guide other TTVr (e.g., edge-to-edge, annuloplasty) and even transcatheter tricuspid replacement procedures. Our paper aims to demonstrate the feasibility of using 4D transesophageal echocardiographic (TEE) guidance to perform BASILICA during TAVR.

Our patient was an 84-year-old woman who presented with symptomatic severe native aortic valve stenosis and was deemed high risk for surgery due to her chronic kidney disease and frailty. Multidetector computed tomography revealed a tall left aortic valve cusp with low left main coronary ostium and sinus heights (Figures 1 and 2) . Our team decided to perform BASILICA to avoid left main coronary obstruction during TAVR.

Four-dimensional TEE is a valuable complement to fluoroscopy in guiding the BASILICA procedure to prevent coronary obstruction in TAVR (Figures 3 to 24) (3). However, in BASILICA, in valve-in-valve TAVR with stented bioprosthetic valves that have failed, 4D TEE may be limited in its usefulness due to acoustic shadowing of the bioprosthetic valve stent frame against the catheters and the bioprosthetic valve leaflet. 

The initial response to the COVID-19 pandemic resulted in a significant reduction of nonurgent medical and imaging activity. As we move on from this phase of "lockdown," we need to balance the risks of infection with the risk posed by inadequate management of chronic medical conditions. Where we stand with this balance depends on community prevalence of active disease. The notion of "ramping up" assumes that transmission rate is falling, or low and stable, and will vary by region and country. There will likely continue to be regional flares of COVID-19 infection and possibly times that laboratories need to revert to an emergency posture, similar to earlier phases of the pandemic. In an environment of lower infective risk, the emphasis is changing to appropriate use (Central Illustration). The appropriate use criteria are widely accepted (15) (16) (17) (18) (19) . Although there will always be exceptions to "rarely appropriate" indications, based on the patient's clinical setting, particular attention should be paid to routine studies in asymptomatic patients. In the post-COVID-19 era, the known financial implications of redundant testing are compounded by other safety aspects outlined above. It remains difficult to provide uniform guidelines about test selection because this is often dependent on local availability, quality, and expertise. Nonetheless, now more than ever, there is the need to develop a consensus approach to, for example, noninvasive testing for coronary artery disease (CAD) or quantification of valvular heart disease at a local level.

During the acute phase of the pandemic, there was a massive reduction in the performance of TEE.

However, as TEE remains the most reliable imaging approach for the detection and assessment of bacterial endocarditis, its increased use with appropriate precautions is warranted (20 era are the following (4,7,36,37) ( Table 3) : Identifying patients with CAD who can be treated conservatively (e.g., by excluding high-risk anatomy or through the use of CT-fractional flow reserve to exclude functionally significant lesions). (15, 18, 19, 21) . The advent of rapid protocols as well as real-time and single-heartbeat data acquisition ameliorates this situation and decreases the staff and room exposure time (38) (39) (40) To the best of our knowledge, the present study was the first to demonstrate a significant correlation between calcium and LCBI scores, with significantly higher calcium scores in segments, with a higher LCBI score. This suggests that both plaque characteristics should not be seen as separate entities that might independently predict future adverse events.

Combining calcium burden with LCBI score has the potential to improve the detection of vulnerable plaques and improve individual risk assessment. patients without NAFLD (revascularization, n ¼ 13;

ACS, n ¼ 3; CV death, n ¼ 2; heart failure, n ¼ 4).

Kaplan-Meier analysis showed that patients with NAFLD experienced more CV events than those without NAFLD during follow-up ( Figure 1A) .

Stepwise Interestingly, higher pack-year smoking history was associated with lower risk for ATAA, although the effect size was small. These findings may aid in targeted screening of patients with ATAA to facilitate timely surgical intervention.

The tertiary care setting may limit the generalizability of our findings, although we excluded external scans to minimize the bias related to referrals.

Because the scans were obtained for various indications, related selection bias must be considered.

However, the scans encompassed all encounter settings, and the large cohort and sample heterogeneity may allow generalization of the predictors of ATAA.

Pertinent genetic disorders were not present on the basis of medical history data, but this may be due to Values are median (interquartile range) or n (%). Bold signifies statistical significance (p < 0.05). *OR, 95% CI, and p value were derived from a multivariate logistic regression model using all variables in the table as covariates.

BSA ¼ body surface area by Mosteller equation; CI ¼ confidence interval; OR ¼ odds ratio. PDs were mixed on the importance of imaging certification examinations. Almost one-half (48%)

found them important, 34% were neutral, and 16% did not think they were important. Regarding examination content, 14% favored a single integrated multimodality examination, 48% favored a modular examination allowing for modality specific modules, 28% favored each modality having its own examination, and 6% favored having no certification examinations.

In the past 2 years, 62% of programs had graduates take imaging focused jobs in academic centers, and 

Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure

The right ventricle: anatomy, physiology and clinical imaging

Echocardiographic manifestations of left bundle branch block

Mechanism of abnormal interventricular septal motion during delayed left ventricular activation

Long-term outcome after CRT in the presence of mechanical dyssynchrony seen with chronic RV pacing or intrinsic LBBB

Mechanisms of abnormal systolic motion of the interventricular septum during left bundle-branch block

Assessment of apical rocking: a new, integrative approach for selection of candidates for cardiac resynchronization therapy

Ventricular interdependence: significant left ventricular contributions to right ventricular systolic function

Comparative electromechanical and hemodynamic effects of left ventricular and biventricular pacing in dyssynchronous heart failure: electrical resynchronization versus left-right ventricular interaction

Combining computer modelling and cardiac imaging to understand right ventricular pump function

Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

Defining left bundle branch block in the era of cardiac resynchronization therapy

Postsystolic shortening in ischemic myocardium: active contraction or passive recoil?

Cardiac responses to left ventricular pacing in hearts with normal electrical conduction: beneficial effect of improved filling is counteracted by dyssynchrony

Right ventricular architecture responsible for mechanical performance: unifying role of ventricular septum

Afterload hypersensitivity in patients with left bundle branch block

A novel clinical method for quantification of regional left ventricular pressure-strain loop area: a noninvasive index of myocardial work

Mechanism of abnormal septal motion in left bundle branch block: role of left ventricular wall interactions and myocardial scar

Anatomy, echocardiography, and normal right ventricular dimensions

Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment

Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation

Ischemic mitral regurgitation and risk of heart failure after myocardial infarction

T2 mapping and T2* imaging in heart failure

Novel therapeutic and diagnostic management of heart transplant patients

Comprehensive plaque assessment by coronary CT angiography

Histogram analysis of lipid-core plaques in coronary computed tomographic angiography: ex vivo validation against histology

Prognostic value of noninvasive cardiovascular testing in patients with stable chest pain: insights from the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain)

Calcium imaging and selective computed tomography angiography in comparison to functional testing for suspected coronary artery disease: the multicentre, randomized CRESCENT trial

CAD-RADS Coronary Artery Disease Reporting and Data System: an expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Radiology (ACR) and the North American Society for Cardiovascular Imaging (NASCI). Endorsed by the American College of Cardiology

PROspective Multicenter Imaging Study for Evaluation of chest pain: rationale and design of the PROMISE trial

Central core laboratory versus site interpretation of coronary CT angiography: agreement and association with cardiovascular events in the PROMISE trial

Regression models and life-tables

Nonparametric estimation from incomplete observations

Evaluating the yield of medical tests

Outcomes of anatomical versus functional testing for coronary artery disease

CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an openlabel, parallel-group, multicenter trial

Explaining the decrease in US deaths from coronary disease

One-year cardiovascular event rates in outpatients with atherothrombosis

Update in therapeutic approaches to plaque stabilization

Elevation in serum troponin I predicts the benefit of tirofiban

Cardiac troponin assays: guide to understanding analytical characteristics and their impact on clinical care

Singlemolecule counting of high-sensitivity troponin I in patients referred for diagnostic angiography: results from the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular Diseases) study

Single-molecule hsTnI and short-term risk in stable patients with chest pain

High-sensitivity troponin I and coronary computed tomography in symptomatic outpatients with suspected CAD: insights from the PROMISE Trial

Highsensitivity troponin I is associated with highrisk plaque and MACE in stable coronary artery disease

High-sensitivity cardiac troponin, statin therapy, and risk of coronary heart disease

Empagliflozin ameliorates

Myocardial efficiency and sympathetic reinnervation after orthotopic heart transplantation: a noninvasive study with positron emission tomography

Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism

A novel clinical method for quantification of regional LV pressure-strain loop area: a non-invasive index of myocardial work

Assessment of wasted myocardial work: a novel method to quantify energy loss due to uncoordinated left ventricular contractions

Wasted septal work in LV dyssynchrony: a novel principle to predict response to cardiac resynchronization therapy

Value of myocardial work estimation in the prediction of response to cardiac resynchronization therapy

myocardial oxygen consumption and efficiency in patients with cardiac amyloidosis

Myocardial oxygen uptake is unchanged but efficiency is reduced in patients with essential hypertension and LV hypertrophy

Hypertensive LV hypertrophy is associated with abnormal myocardial fatty acid metabolism and myocardial efficiency

Reduced mechanical efficiency in left-ventricular trabeculae of the spontaneously hypertensive rat

Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy

Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction

Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations

Effects of propranolol on myocardial oxygen uptake, substrate extraction, and haemodynamics in hypertrophic obstructive cardiomyopathy

Myocardial efficiency is an important determinant of functional improvement after aortic valve replacement in aortic valve stenosis patients: a combined PET and CMR study

Automatic calculation of myocardial external efficiency using a single 11 C-acetate PET scan

Effects of mitral valve surgery on myocardial energetics in patients with severe mitral regurgitation

ACCF/AHA guideline for the management of STelevation myocardial infarction

AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes

Fractional flow reserve guided PCI versus medical therapy in stable coronary disease

Novel index for invasively assessing the coronary microcirculation

Nonobstructive coronary artery disease and risk of myocardial infarction

Heart failure with preserved ejection fraction: is ischemia due to coronary microvascular dysfunction a mechanistic factor?

Reversible coronary microvascular dysfunction: a common pathogenetic mechanism in apical ballooning or tako-tsubo syndrome

Targeting the dominant mechanism of coronary microvascular dysfunction with intracoronary physiology tests

Coronary microvascular dysfunction

Morphometry of pig coronary venous system

Anatomy and physiology of coronary blood flow

Coronary arteriolar myogenic response is independent of endothelium

Coronary microcirculation in health and disease: summary of an NHLBI workshop

Determinants of myocardial blood flow response to cold pressor testing and pharmacologic vasodilation in healthy humans

International standardization of diagnostic criteria for microvascular angina

Intracoronary bolus injection versus intravenous infusion of adenosine for assessment of coronary flow velocity reserve in women with signs and symptoms of myocardial ischemia and no obstructive coronary artery disease

Coronary microvascular dysfunction, microvascular angina, and treatment strategies

Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction

Coronary microvascular function and myocardial fibrosis in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study

Myocardial blood flow by PET: technical aspects and clinical applications

Quantification of myocardial perfusion and myocardial perfusion reserve by positron emission tomography and cardiovascular magnetic resonance imaging

Increased myocardial perfusion at rest and diminished perfusion reserve in patients with angina and angiographically normal coronary arteries

Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia

Improved cardiac risk assessment with noninvasive measures of coronary flow reserve

In vivo myocardial kinetics of air-filled albumin microbubbles during myocardial contrast echocardiography. Comparison with radiolabeled red blood cells

Myocardial blood volume is associated with myocardial oxygen consumption: an experimental study with cardiac magnetic resonance in a canine model

Early changes in myocardial microcirculation in asymptomatic hypercholesterolemic subjects: as detected by perfusion CT

The relative myocardial blood volume differentiates between hypertensive heart disease and athlete's heart in humans

Arterial input function in perfusion MRI: a comprehensive review

Myocardial blood flow quantification for evaluation of coronary artery disease by positron emission tomography, cardiac magnetic resonance

Myocardial perfusion modeling using MRI

Dynamic single photon emission computed tomography-basic principles and cardiac applications

Equations for measuring blood flow by external monitoring of radioisotopes

Static and dynamic assessment of myocardial perfusion by computed tomography

Quantification of myocardial perfusion using dynamic 64-detector computed tomography

Coronary microvascular dysfunction: mechanisms and functional assessment

Computational fluid dynamics applied to cardiac computed tomography for noninvasive quantification of fractional flow reserve: scientific basis

Prospective Comparison of FFR Derived From Coronary CT Angiography With SPECT Perfusion Imaging in Stable Coronary Artery Disease: the ReASSESS study

Diagnostic performance of non-invasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial

Coronary lumen volume to myocardial mass ratio in primary microvascular angina

ESC guidelines on the management of stable coronary artery disease

Adenosine-induced stress myocardial perfusion imaging using dual-source cardiac computed tomography

The effects of ionic and nonionic radiographic contrast media on coronary hyperemia in patients during coronary angiography

First-pass entry of nonionic contrast agent into the myocardial extravascular space. Effects on radiographic estimates of transit time and blood volume

The role of PET quantification in cardiovascular imaging

Noninvasive assessment of myocardial perfusion

Quantification of regional myocardial blood flow in vivo with H

Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health

Radiation dose to patients from cardiac diagnostic imaging

Quantification of myocardial blood flow with 82 Rb dynamic PET imaging

Quantification of myocardial blood flow using N-13-ammonia and PET: comparison of tracer models

Reproducibility and accuracy of quantitative myocardial blood flow assessment with (82)Rb PET: comparison with (13)N-ammonia PET

Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET

the St James Women Take Heart Project

Added prognostic value of myocardial blood flow quantitation in rubidium-82 positron emission tomography imaging

Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review

Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction

Coronary circulatory function in patients with the metabolic syndrome

Coronary physiology beyond coronary flow reserve in microvascular angina: JACC state-of-the-art review

Feasibility of dynamic stress 201Tl/rest 99mTc-tetrofosmin single photon emission computed tomography for quantification of myocardial perfusion reserve in patients with stable coronary artery disease

Quantification of myocardial blood flow with dynamic SPECT acquisitions: ready for prime time?

Absolute quantification of myocardial perfusion under adenosine stress

Quantitative magnetic resonance perfusion imaging detects anatomic and physiologic coronary artery disease as measured by coronary angiography and fractional flow reserve

Assessment of advanced coronary artery disease: advantages of quantitative cardiac magnetic resonance perfusion analysis

Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging

Diagnostic performance of fully automated pixel-wise quantitative myocardial perfusion imaging by cardiovascular magnetic resonance

Comparison of the diagnostic performance of four quantitative myocardial perfusion estimation methods used in cardiac MR imaging: CE-MARC substudy

Absolute myocardial perfusion in canines measured by using dual-bolus first-pass MR imaging

The BASILICA trial: prospective multicenter investigation of intentional leaflet laceration to prevent TAVR coronary obstruction

Preventing coronary obstruction during transcatheter aortic valve replacement: from computed tomography to BASILICA

Impact of initial Evolut TAVR deployment orientation on final valve orientation and coronary reaccess: a pilot study

Department of Radiology, Brigham and Women's Hospital

Baylor Scott and White Heart and Vascular Hospital, Dallas Texas; j Cardiovascular Center, Division of Cardiology

Institute of Experimental and Translational Cardiac Imaging, German Centre for Cardiovascular Research (DZHK) Centre for Cardiovascular Imaging, University Hospital Frankfurt

The views expressed in this paper by the American College of Cardiology's Imaging Section and

Blankstein has received research support from Amgen Inc. and Astellas Inc. Dr. Jaffer has received research support from Canon and Siemens Healthineers; and has served as a speaker for Siemens Healthineers and Biotronik

Leipsic has received grant support from GE Healthcare and Edwards Lifesciences; and has served on the Speakers Bureau for GE Healthcare and Philips; and has served as a consultant for and owns stock options in Circle Cardiovascular Imaging and HeartFlow

Salerno has received research support from Siemens Healthineers. Dr. Sengupta has served as an advisor to Ultromics, HeartSciences, and Kencor Health

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, 1. Centers for Disease Control and Prevention. Coronavirus (COVID-19)

ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak

Guidance and best practices for nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An Information Statement from ASNC and SNMMI

Society of

Society for Cardiovascular Magnetic Resonance

COVID-19 preparedness toolkit

COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and health care personnel

European Society of Cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 Pandemic

Safe reintroduction of cardiovascular services during the COVID-19 pandemic: guidance from North American Society Leadership

ASE statement on the reintroduction of echocardiography services during the COVID-19 pandemic

Guidance and best practices for reestablishment of nonemergent care in nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: an information statement from ASNC, IAEA, and SNMMI

Society for Cardiovascular Magnetic Resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic

Variation in false-negative rate of reverse transcriptase polymerase chain reactionbased SARS-CoV-2 tests by time since exposure

Detection of SARS-CoV-2 in different types of clinical specimens

Food & Drug Administration. FAQs on testing for SARS-CoV-2. Available at: https:// www.fda.gov/medical-devices/emergency-situationsmedical-devices/faqs-testing-sars-cov-2?utm_ campaign¼2020-05-18%20CDRH%20New&utm_ medium¼email&utm_source¼Eloqua

Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons

the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society

Cardiovascular Imaging in the COVID-19 Pandemic for Cardiovascular Magnetic Resonance

American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association

Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians

appropriate use criteria for multimodality imaging in valvular heart disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery

Appropriate Use Criteria for Multimodality Imaging in the Assessment of Cardiac Structure and Function in Nonvalvular Heart Disease: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery

ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC) endorsed by: European Association for Cardio-Thoracic

European Association of Nuclear Medicine (EANM)

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prognostic value of right ventricular longitudinal strain in patients with COVID-19

ASE statement on pointof-care ultrasound (POCUS) during the 2019 novel coronavirus pandemic

Clinical applications of ultrasonic enhancing agents in echocardiography

Myocardial viability: survival mechanisms and molecular imaging targets in acute and chronic ischemia

ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures

Cardiovascular imaging techniques to assess microvascular dysfunction

Joint SNMMI-ASNC Expert Consensus document on the role of (18)F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring

Nonbiopsy diagnosis of cardiac transthyretin amyloidosis

FDG PET/CT for early detection and localization of left ventricular assist device infection: impact on patient management and outcome

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

Coronary CT angiography in patients with non-ST-segment elevation acute coronary syndrome

Initial imaging-guided strategy versus routine care in patients with non-ST-segment elevation myocardial infarction

Quadruple rule out" with cardiac computed tomography in COVID-19 patient with equivocal acute coronary syndrome presentation

Cardiac CTA for evaluation of prosthetic valve dysfunction

Comparison of cardiac computed tomography with transesophageal echocardiography for identifying vegetation and intracardiac complications in patients with infective endocarditis in the era of 3-dimensional images

CMR first-pass perfusion for suspected inducible myocardial ischemia

High-throughput gadobutrol-enhanced CMR: a time and dose optimization study

Rapid Cardiovascular Magnetic Resonance for Ischemic Heart Disease Investigation (RAPID-IHD)

Cardiac MRI for detecting left atrial/left atrial appendage thrombus in patients with atrial fibrillation : Meta-analysis and systematic review

Detection of LA and LAA thrombus by CMR in patients referred for pulmonary vein isolation

Medtronic, and PulseCath; and has received consultancy and speaker fees from Acist Medical, Medtronic, PulseCath, Boston Scientific, and ReCor Medical. the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information

Calcifications in atherosclerotic plaques and impact on plaque biomechanics

Detection of lipid core coronary plaques in autopsy specimens with a novel catheter-based near-infrared spectroscopy system

The ability of high dose rosuvastatin to improve plaque composition in non-intervened coronary arteries: rationale and design of the Integrated Biomarker and Imaging Study-3 (IBIS-3)

Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions

Cardioonco-hematology in clinical practice

Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity

First magnetic resonance managed by a cardiology department in the Spanish public healthcare system. Experience and difficulties of an innovative model

Early detection of anthracycline-induced cardiotoxicity in breast cancer survivors with T2 cardiac magnetic resonance

Cardiovascular toxic effects of targeted cancer therapies

CMR first-pass perfusion for suspected inducible myocardial ischemia

Effect of care guided by CMR, MPS, or NICE guidelines on subsequent unnecessary angiography rates: a randomized trial (CE-MARC 2)

Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease

Feasibility study of a single breathhold, 3D mDIXON pulse sequence for late gadolinium enhancement imaging of ischemic scar

Comparison of the diagnostic performance of four quantitative myocardial perfusion estimation methods used in cardiac MR imaging: CE-MARC substudy

Diabetes and reduced risk for thoracic aortic aneurysms and dissections: a nationwide case-control study

Thoracic and abdominal aortic aneurysms

Differences in atherosclerotic profiles between patients with thoracic and abdominal aortic aneurysms

Prevalence of incidentally identified thoracic aortic dilations: insights for screening criteria

Thoracic aortic aneurysm clinically pertinent controversies and uncertainties

but both were significantly larger compared with patients with M OD -AS (146 pg/ml [range 66 to 357 pg/ml] and 1,018 AU

Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography

Paradoxical low-flow, lowgradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival

Inconsistencies of echocardiographic criteria for the grading of aortic valve stenosis

E-mail: Gaby.weissman@medstar

Please note: Dr. Weissman directs an academic cardiovascular imaging core laboratory with institutional contracts with Abbott, Ancora Heart, Boston Scientific, LivaNova, and Medtronic. Dr. Lee has served as a consultant for Heartflow. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information

CV imaging for fellows in training: challenges and opportunities

Employment status after training in advanced CV imaging

Current state of advanced cardiovascular imaging training in the United States

org/About-Us/Publications-and-Resources/Graduate-Medical-Education-Data-Resource-Book

Evolocumab and clinical outcomes in patients with cardiovascular disease

Alirocumab and cardiovascular outcomes after acute coronary syndrome

Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial

 (7):1615-26.The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Imaging author instructions page.

The left aortic valve cusp is positioned at the top (arrow) (Video 1). 3D ¼ 3-dimensional; TEE ¼ transesophageal echocardiography. In conclusion, using protocolized computed tomography-based definition of ATAA, we demonstrated that diabetes was associated with reduced risk for ATAA, while hypertension was associated with increased risk for ATAA. Other atherosclerotic risk factors (chronic kidney disease, myocardial infarction) were not predictive, suggesting that atherosclerotic process may not be a primary driver of ascending aortic aneurysm formation. Please note: The authors have reported that they have no relationships relevant to the contents of this paper to disclose.The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Imaging author instructions page. Please note: All authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Imaging author instructions page.